Global PNH & aHUS Market: Industry Analysis & Outlook (2017-2021)

  • ID: 4420911
  • Report
  • Region: Global
  • 69 Pages
  • Koncept Analytics
1 of 5
Progress in Drug Pipeline to Boost PNH and aHUS Market

FEATURED COMPANIES

  • Omeros Corporation
  • RA Pharmaceuticals Inc.
  • MORE

PNH and aHUS, both are extremely rare and genetic diseases. Due to PNH, destruction of red blood cells of a person occurs quite sooner than it should. It is an acquired hematopoietic stem cell disorder. Hematopoietic stem cells are developed in bone marrow and eventually turn into red blood cells, white blood cells and platelets. A person with PNH has some defected hematopoietic cells which create defective red blood cells. These defective cells are highly susceptible to premature destruction by the complement system. aHUS is a disorders in which blood clots are formed in small blood vessels throughout the body. TMA can lead to heart stroke, attack, kidney failure and death. Soliris is the only drug treatment available in the market for treating these diseases.

Regionally, Europe held the largest share in the global PNH drug market and the U.S. dominated the global aHUS drug market, supported by favorable reimbursement policies In terms of patient population, Asia-pacific region had the highest number of PNH and aHUS patients. With the increasing technological advancements in diagnosis techniques of PNH and aHUS, the number of diagnosed patients is likely to grow globally.

The global PNH and aHUS market is expected to grow in future due to prolonged orphan drug market exclusivity, attractive orphan drug policies, increasing pharmaceutical R&D expenditure, rising health care expenditure. Key trends of this market include progressing drugs under pipeline, increasing prevalence of blood and bone marrow related disorders and favorable reimbursement policies. However, there are some factors which can hinder the market growth including high costs of drugs and associated risks.

The report “Global PNH and aHUS Market: Industry Analysis & Outlook (2017-2021)” provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the U.S., Europe and Asia-Pacific region along with the global market. The report profiles the key players of the market including Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc, Omeros Corporation and RA Pharmaceuticals.

READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Omeros Corporation
  • RA Pharmaceuticals Inc.
  • MORE

1. Overview
1.1 Introduction to PNH
1.2 Symptoms and Diagnosis of PNH
1.3 Treatment of PNH
1.4 Introduction to aHUS
1.5 Symptoms and Diagnosis of aHUS
1.6 Treatment of aHUS

2. Global PNH and aHUS Market
2.1 PNH Patient Population
2.2 PNH Drug Market Value Forecast
2.3 PNH Drug Market by Type
2.4 PNH Drug Market by Region
2.5 aHUS Patient Population Forecast
2.6 aHUS Drug Market Value Forecast
2.7 aHUS Drug Market by Type
2.8 aHUS Drug Market by Region

3. Regional Market
3.1 The U.S.
3.1.1 The U.S. PNH Patient Population Forecast
3.1.2 The U.S. PNH Drug Market Value Forecast
3.1.3 The U.S. aHUS Patient Population Forecast
3.1.4 The U.S. aHUS Drug Market Value Forecast
3.2 Europe
3.2.1 Europe PNH Patient Population Forecast
3.2.2 Europe PNH Drug Market Value Forecast
3.2.3 Europe aHUS Patient Population Forecast
3.2.4 Europe aHUS Drug Market Value Forecast
3.3 Asia-Pacific
3.3.1 Asia-Pacific PNH Population Forecast
3.3.2 Asia-Pacific PNH Drug Market- Soliris Sales Value Forecast
3.3.3 Asia-Pacific aHUS Patient Population Forecast
3.3.4 Asia-Pacific aHUS Drug Market- Soliris Sales Value Forecast

4. Market Dynamics
4.1 Growth Drivers
4.1.1 Prolonged Orphan Drug Market Exclusivity
4.1.2 Attractive Orphan Drug Development Policies
4.1.3 Increasing Pharmaceutical R&D Spending
4.1.4 Rising Healthcare Expenditure
4.2 Key Trends & Developments
4.2.1 Progressing Drugs under Pipeline
4.2.2 Favorable Reimbursement Policies
4.2.3 Increasing Prevalence of Blood and Bone Marrow Related Disorders
4.3 Challenges
4.3.1 High Prices of Drugs
4.3.2 Other Associated Risks

5. Competitive Landscape
5.1 Global Market
5.1.1 Revenue Comparison of Key Companies
5.1.2 Market Cap Comparison of Key Companies

6. Company Profiles
6.1 Alexion Pharmaceuticals Inc.
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Alnylam Pharmaceuticals, Inc.
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Omeros Corporation
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 RA Pharmaceuticals Inc.
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies

List of Charts

  • Global PNH Patient Population Forecast (2016-2021)
  • Global PNH Drug Market Value Forecast (2016-2021)
  • Global PNH Drug Market by Type (2016/2021)
  • Global PNH Drug Market Value by Region (2016)
  • Global aHUS Patient Population Forecast (2016-2021)
  • Global aHUS Drug Market Value Forecast (2016-2021)
  • Global aHUS Drug Market by Type (2016/2021)
  • Global aHUS Drug Market Value by Region (2016)
  • The U.S. PNH Patient Population Forecast (2016-2021)
  • The U.S. PNH Drug Market Value Forecast (2016-2021)
  • The U.S. aHUS Patient Population Forecast (2016-2021)
  • The U.S. aHUS Drug Market Value Forecast (2016-2021)
  • Europe PNH Patient Population Forecast (2016-2021)
  • Europe PNH Drug Market Value Forecast (2016-2021)
  • Europe aHUS Patient Population Forecast (2016-2021)
  • Europe aHUS Drug Market Value Forecast (2016-2021)
  • Asia-Pacific PNH Population Forecast (2016-2021)
  • Asia-Pacific PNH Drug Market- Soliris Sales Value Forecast (2016-2021)
  • Asia-Pacific aHUS Patient Population Forecast (2016-2021)
  • Asia-Pacific aHUS Drug Market- Soliris Sales Value Forecast (2016-2021)
  • Global Pharmaceutical R&D Spending (2012-2016)
  • Global Healthcare Expenditure per Capita (2012-2016)
  • Revenue Comparison of Key Companies (2016)
  • Market Cap Comparison of Key Companies (2016)
  • Alexion Pharmaceuticals Inc. Sales by Product (2016)
  • Alexion Pharmaceuticals Inc. Total Revenue & Net Income (2012-2016)
  • Alexion Pharmaceuticals Inc. R&D Expenditure (2014-2016)
  • Alnylam Pharmaceuticals, Inc. Net Revenue & Net Loss (2012-2016)
  • Alnylam Pharmaceuticals, Inc. R&D Expenditure (2014-2016)
  • Omeros Corporation Revenue and Net Loss (2012-2016)
  • Omeros Corporation R&D Expenditure (2014-2016)
  • RA Pharmaceuticals Inc. Revenue & Net Loss (2012-2016)
  • RA Pharmaceuticals Inc. R&D Expenditure (2014-2016)

List of Tables

  • Orphan Drug Market Exclusivity
  • Orphan Drug Policies by Region
  • Drugs under Development for PNH and aHUS (2016)
  • Alnylam Pharmaceuticals, Inc. Drug Pipeline (2016)
  • Omeros Corporation Clinical Drug Development Programs (2016)
  • RA Pharmaceuticals Inc. Drug Pipeline (2016)
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Alexion Pharmaceuticals Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Omeros Corporation
  • RA Pharmaceuticals Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll